Oncology

Reports of high-impact oncology studies by medical professionals

The REACH trial: hydroxyurea safe and effective for sickle cell anemia in African children

1. Among sub-Saharan African children with sickle cell anemia (SCA) treated with hydroxyurea, 5.1% experienced dose-limiting toxic events, well below the protocol-specified allowable rate...

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

1. A hybrid minimally invasive esophagectomy approach (Ivor-Lewis esophagectomy) was found to have lower rates of intraoperative and postoperative complications after 30 days as...

Screening all donated blood for Zika virus is not cost-effective in the United States

1. This microsimulation study suggested that screening blood for Zika virus is only cost-effective during the high mosquito season in Puerto Rico.2. The authors...

The VITAL trial: Omega-3 supplementation does not reduce risk of cardiovascular events

1. Healthy adult patients randomized to receive marine n-3 fatty acids (omega-3) experienced similar rates of adverse cardiovascular events as those receiving a placebo...

Quick Take: Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally...

Ovarian function suppression (OFS) is considered an important aspect of treatment in premenopausal women with advanced endocrine-responsive breast cancer. Degarelix is a gonadotropin-releasing hormone...

Quick Take: Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with...

The optimal duration of androgen suppression therapy with radiotherapy for locally advanced prostate cancer is unknown. In 2018, the French Canadian Prostate Cancer Study...

Quick Take: Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results...

Hepatocellular carcinoma (HCC) is a rapidly increasing cause of morbidity and mortality in patients affected by HIV. However, the impact of HIV infection on...

The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer

1. In women with BRCA-associated, newly diagnosed advanced ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo.2. The majority...

New molecular probes for melanoma imaging and treatment [PreClinical]

1. α-melanocyote stimulating hormone (α -MSH) and its analogs can bind tightly to the melanocortin-1 receptor (MC1R), a G protein-coupled receptor that is overexpressed...

Quick Take: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Neoantigens are derived from tumor-specific somatic mutations. As such, they are exempt from immune central tolerance mechanisms and can generate robust immune responses, making...

All-time hits

licensing as small